14:45 EDT Outlook jumps 24% to $1.64 after FDA approves wet AMD treatmentClaim 55% Off TipRanks Unlock powerful investing tools with TipRanks Pr...
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on OTLK:Disclaimer & DisclosureReport an Issue
Outlook Therapeutics Inc trading halted, news pending
Outlook Therapeutics Grants Incentive Awards Tied to FDA Approval
Outlook Therapeutics Inc. shares are trading higher Tuesday after the FDA granted its appeal in the ONS-5010 dispute resolution…
Outlook Therapeutics has notched a win in its uphill battle to commercialize an ophthalmic version of Roche’s Avastin…
Outlook Therapeutics shares rose after the FDA accepted its resubmitted LYTENAVA BLA and set a July 2026 target action date.
19:50 EDT ADiTx Therapeutics trading halted, news pendingClaim 55% Off TipRanksUnlock hedge fund-level data and powerful…
Outlook Therapeutics said the agency has reversed course regarding its reformulated version of Avastin for the eye condition…
Ocular outlines FDA-aligned AXPAXLI NDA plan for wet AMD by Q4 2026, revises SOL-R study design, and streamlines DR program.
